Regeneron (REGN) Completes Checkmate Pharmaceuticals Acquisition May 31, 2022 08:36AM
Pre-Open Stock Movers 04/19: Super Micro and American Campus Higher; NETGEAR and Stellantis Lower (more...) Apr 19, 2022 09:24AM
Regeneron (REGN) Acquires Checkmate Pharmaceuticals (CMPI) for $10.50/sh Cash Apr 19, 2022 07:00AM
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types Apr 19, 2022 07:00AM
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types Apr 19, 2022 07:00AM
View Older Stories

Apr 19, 2022 07:00AM Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
Feb 9, 2022 08:00AM Checkmate Pharmaceuticals (CMPI) Appoints Alan Bash as President and CEO
Feb 9, 2022 08:00AM Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO
Feb 9, 2022 08:00AM Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO
Jan 31, 2022 04:31PM Checkmate Pharmaceuticals (CMPI) Appoints Jon Wigginton to its Board
Jan 31, 2022 04:30PM Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors
Jan 31, 2022 04:30PM Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors
Jan 3, 2022 04:30PM Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
Jan 3, 2022 04:30PM Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
Dec 20, 2021 07:05AM Checkmate Pharmaceuticals (CMPI) Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D.
Dec 20, 2021 07:00AM Checkmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D.
Dec 20, 2021 07:00AM Checkmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D.
Dec 20, 2021 07:00AM Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using Vidutolimod
Dec 20, 2021 07:00AM Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using Vidutolimod
Nov 15, 2021 04:30PM Checkmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Nov 15, 2021 04:30PM Checkmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Nov 12, 2021 07:08AM Checkmate Pharmaceuticals (CMPI) Presents Final Clinical Data for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Nov 12, 2021 07:05AM Checkmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
Nov 12, 2021 07:05AM Checkmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
Nov 12, 2021 07:01AM Checkmate Pharmaceuticals Presents Final Clinical Data for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting 
Nov 11, 2021 04:30PM Checkmate Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Nov 11, 2021 04:30PM Checkmate Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Nov 1, 2021 08:01AM Checkmate Pharmaceuticals Announces Final Data Presentation for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Oct 27, 2021 04:31PM Checkmate Pharmaceuticals (CMPI) Announces Alan Fuhrman as New Interim CEO
Oct 27, 2021 04:30PM Checkmate Pharmaceuticals Announces CEO Transition
Oct 27, 2021 04:30PM Checkmate Pharmaceuticals Announces CEO Transition
Oct 20, 2021 04:30PM Checkmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)
Oct 20, 2021 04:30PM Checkmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)
Sep 14, 2021 04:30PM Checkmate Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
Sep 14, 2021 04:30PM Checkmate Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
Sep 7, 2021 07:00AM Checkmate Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 7, 2021 07:00AM Checkmate Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 12, 2021 04:30PM Checkmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update
Aug 12, 2021 04:30PM Checkmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update
Aug 2, 2021 04:15PM Checkmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
May 20, 2021 04:30PM Checkmate Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
May 20, 2021 04:30PM Checkmate Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
May 13, 2021 04:10PM Checkmate Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Update on Recent Progress
May 13, 2021 04:10PM Checkmate Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Update on Recent Progress
May 10, 2021 06:13AM Checkmate Pharmaceuticals (CMPI) Announces Clinical Supply Agreement with Regeneron (REGN) to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo
May 10, 2021 06:00AM Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo® (cemiplimab)
May 10, 2021 06:00AM Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo® (cemiplimab)
May 4, 2021 07:00AM Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod (CMP-001) in Patients with Anti-PD-1 Refractory Advanced Melanoma
May 4, 2021 07:00AM Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod (CMP-001) in Patients with Anti-PD-1 Refractory Advanced Melanoma
Apr 28, 2021 04:30PM Checkmate Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
Apr 28, 2021 04:30PM Checkmate Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
Apr 19, 2021 06:01AM Checkmate Pharmaceuticals (CMPI) Begins Patient Dosing in Phase 2 Head and Neck Cancer Trial
Apr 19, 2021 06:00AM Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Head and Neck Cancer Trial
Apr 19, 2021 06:00AM Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Head and Neck Cancer Trial
Apr 11, 2021 04:01PM Checkmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at the 2021 American Association for Cancer (AACR) Annual Meeting
View Older Stories